Navigation Links
InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
Date:11/17/2011

several corporations.  

Asher Holzer added, "I am pleased that Dr. Barer has agreed to become chairman of InspireMD, and I am confident that his experience will help the Company reach the next level."

About InspireMD Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
2. InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco
3. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
4. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
5. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
6. County of Los Angeles Selects Netsmart to Provide Comprehensive Behavioral Health Information System
7. The American Ceramic Society selects Marshall, Niihara as 2011 Distinguish Life Members
8. H. D. Smith Selects IT Industry Executive David Guzman as CIO
9. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
10. EdgeBio Selects Calipers Sample Preparation Suite for High Throughput and Benchtop Sequencing Workflows
11. St. Lukes Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)...  Select Medical Corporation ("Select") (NYSE: SEM ... early termination of the waiting period under the ... amended, applicable to the acquisition of Concentra Inc. ... that Select has created with Welsh, Carson, Anderson & ... MJ Acquisition Corporation has signed a definitive purchase ...
(Date:5/20/2015)...  Marc Tessier-Lavigne, president of The Rockefeller University, ... from The Marie-Josée and Henry R. Kravis Foundation ... will be the centerpiece of the University,s major ... Kravis Research Building, two stories high, will be ... city blocks following the shoreline of the East ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var ...
... Nov. 16, 2010 AVANIR Pharmaceuticals, Inc. ... intends to offer and sell shares of its common stock ... acting as sole book-running manager in the offering and Canaccord ... and Merriman Capital are acting as co-managers for the offering. ...
... ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, ... in vitro data demonstrating that the ... substrates for the human Organic Anion Transporters (hOATs) ... nephrotoxicity via this mechanism.  These data, presented at ...
Cached Biology Technology:Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 2Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 3Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 4Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 5Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 6Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 7Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 8Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 9AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
... far the most successful life form on Earth. As ... spaceflight, they don,t do too badly in microgravity either. ... cosmonauts who were stricken with infections during their flights. ... treatments against most harmful bacteria. But previous studies have ...
... to choose healthy options at the grocery store if they ... as a motivational tool, according to new research published in ... Psychological Science. The research adds to a body of ... increasing healthy behaviors, a growing concern for many different groups, ...
... and was approved for the treatment of neuropathic pain ... However, little evidence is available on the effects and ... period. A recent study by Yanbo Zhang and colleague ... that excitatory amino acids and protein kinase C are ...
Cached Biology News:Beating bacteria on Earth -- and in space 2Beating bacteria on Earth -- and in space 3Beating bacteria on Earth -- and in space 4Laying money on the line leads to healthier food choices over time 2Laying money on the line leads to healthier food choices over time 3
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
PP2B-Abeta (C-20)...
Goat polyclonal to Duffy / FY / DARC...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
Biology Products: